Our news

Crossject will be attending J.P. Morgan Healthcare conference

During the 2nd week of January 2019, Crossject will be in San Francisco around the J.P. Morgan Healthcare Conference, to meet with American pharmaceutical companies.

Read more

ZENEO® Midazolam earns the orphan drug designation

The FDA has granted Orphan Drug designation to ZENEO® Midazolam for the treatment of status epileptics.

ZENEO® receives the JANUS

Crossject is proud to announce that ZENEO® received the 2017 JANUS Prospective award from the French Institute of Design.